Scipher Medicine

Scipher Medicine is a precision immunology company that aims to revolutionize patient treatment. Founded in 2014, the company's slogan "Scipher Medicine is a precision immunology company matching each patient with their most effective therapy" reflects its core mission. The traditional approach to prescribing blockbuster therapies often leads to ineffective treatment for many patients, resulting in significant financial losses for the healthcare industry while patients continue to suffer. Scipher Medicine addresses this challenge by leveraging a platform that identifies the most suitable drug for a patient based on their fundamental disease biology, rather than relying on symptoms, disease classification, or medical bias. Through a simple test, they predict which drug a patient will respond to, ensuring the prescription of the most optimal treatment from the onset. The molecular data generated by their tests also fuel novel target discovery to address unmet medical needs in patients who do not respond to existing therapies. This innovative approach has attracted significant interest from investors, with the latest Series D investment of $110.00M secured on 24 February 2022. The investment was led by a consortium of prominent investors including Khosla Ventures, Optum Ventures, Alumni Ventures Blockchain Fund, aMoon, Cowen Digital, Green D Ventures, Hitachi Ventures, Laurion Capital, Monashee Investment Management, and Neuberger Berman. Operated out of the United States, Scipher Medicine operates within the Biotechnology and Health Care industries, positioning itself at the forefront of precision medicine and immunology. With its compelling value proposition and strong investor backing, Scipher Medicine is poised to drive significant impact in personalized patient care and address critical unmet medical needs.